VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
SNN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
SNNSmith & Nephew plc
$27.50$11.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
SNN logo

Smith & Nephew plc

SNN
NYSE · Medical Devices
$27.50
At close - Sep 22, 4:00 PM EDT - USD
Market Cap$11.55B
P/E19.1x
52W High$37.51
Volume897.68K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Margin Recovery Masks Persistent Leverage and Cash Flow Volatility

Smith & Nephew has demonstrated a solid operational turnaround, with operating margin recovering from 5.3% in 2023Q4 to 14.5% in 2026Q2, driven by cost actions and volume recovery. Revenue growth remains steady at 4.6% in 2026Q2, supported by pricing power in ...

GrowthStable
ProfitabilityModerate
ValuationAttractive
TechnicalsWeak
Explore valuation models
MARKET ACTION

SNN price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

7/12 Beats

EPS beat 7 of last 12 quarters

02

Valuation risk

-32% Peers

P/E is 32% below peer median

03

Market leadership

RS 30 · Lag

Laggard (Underperforming 70% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Nov 4
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue grew 4.6% year-over-year in 2026Q2 with gross margin at 70.9%, but operating margin of 14.5% still lags peers like Stryker (19.5%), indicating structural inefficiencies.

Analyst Consensus+19.0% target
Hold(23 analysts)
6 Buy15 Hold2 Sell

The Bull Case

Upside Catalysts

Strong revenue growth

Smith & Nephew's fourth-quarter revenue of $1.7 billion exceeded Wall Street forecasts by $20 million, driven by an 8.3% year-over-year growth.

Strategic transformation under CEO

The company is undergoing a strategic transformation under CEO Deepak Nath, with the RISE strategy aimed at accelerating revenue growth, expanding profit margins, and enhancing performance.

Positive 2026 guidance

Smith & Nephew's 2026 guidance, unveiled at its 2025 Investor Day, indicates confidence in future growth and profitability.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
SNN-14.90%
S&P 500 (^GSPC)+13.20%
1-Year Return
SNN-22.56%
S&P 500 (^GSPC)+15.98%
3-Year Return
SNN+17.44%
S&P 500 (^GSPC)+79.06%
5-Year Return
SNN-13.87%
S&P 500 (^GSPC)+74.82%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
18.6x
Forward P/EExpansion
12.2x
EV/EBITDA20th %ile
11.2x
FCF YieldCash Flow
7.6%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
18.6x
26.1x
0th· Low
EV/EBITDA
11.2x
13.6x
20th· Low
Price/FCF
13.2x
32.4x
0th· Low
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$58.96+114.4%
Base (Fair)$94.63+243.4%
Bull$183.40+566.9%
$58.96 Bear$94.63 Base$183.40 Bull
Current Market Price: $27.50
Trades at a 70.9% discount to Base DCF ($94.63)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue
$6.16B+6.1% YoY
Net income
$625M+51.7% YoY
Free cash flow
$852M+40.6% YoY
Operating margin
12.9%+1.6 pts YoY
ROIC (TTM)7.4%
Avg ROIC 5Y-
ROE (TTM)11.8%
Piotroski Score7 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate7/12 (58%)
Revenue Beat Rate11/12 (92%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 4, 2026
$0.95+0.7%
vs $0.94
$3.1B+88.9%
vs $1.6B
Q2 2026
Mar 3, 2026
$1.18+1.7%
vs $1.16
$3.2B+15.5%
vs $2.8B
Q2 2026
Mar 2, 2026
$1.18+1.7%
vs $1.16
$3.2B+15.5%
vs $2.8B
Q3 2025
Aug 5, 2025
$0.86+8.6%
vs $0.79
$3.0B+93.5%
vs $1.5B
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

5 Stories
Accesswire·Sep 16, 2026
Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds

Smith+Nephew announces results of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, GB / ACCESS Newswire / September 16, 2026 / Smith+Nephew, the global medical technology company (the "Company") (LSE:SN)(NYSE:SNN), announced today the results of its previously announced offer to purchase for cash (the "Tender Offer"), upon the terms and subject to the conditions set forth in an offer to purchase dated September 8, 2026 (the "Offer to Purchase"), up to U.S.$250 million aggregate principal amount (the "Maximum Tender Amount") of the Company's 2.032% Senior Notes due 2030 (the "Notes") from each registered holder of the Notes (each a "Holder" and collectively, the "Holders"). The Tender Offer was made upon and is subject to the terms and conditions set forth in the Offer to Purchase.

Accesswire·Sep 15, 2026
Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds

Smith+Nephew announces pricing of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, UK / ACCESS Newswire / September 15, 2026 / Smith+Nephew, the global medical technology company (the "Company") (LSE:SN)(NYSE:SNN), announced today the pricing of its previously announced offer to purchase for cash (the "Tender Offer"), upon the terms and subject to the conditions set forth in an offer to purchase dated September 8, 2026 (the "Offer to Purchase"), up to U.S.$250 million aggregate principal amount (the "Maximum Tender Amount") of the Company's 2.032% Senior Notes due 2030 (the "Notes") from each registered holder of the Notes (each a "Holder" and collectively, the "Holders"). The Tender Offer is made upon and is subject to the terms and conditions set forth in the Offer to Purchase.

GuruFocus·Sep 14, 2026
Is It Too Late to Buy Smith & Nephew PLC (SNN) After 3.3% Rally? GF Value Says Undervalued

On September 14, 2026, Smith and Nephew PLC (SNN) shares rose 3.3% to a current price of $28.40. The stock has experienced a 52-week range between $27.23 and $37.

Defense World·Sep 9, 2026
Smith & Nephew SNATS (NYSE:SNN) Hits New 52-Week Low Following Analyst Downgrade

Smith and Nephew SNATS, Inc. (NYSE: SNN - Get Free Report) hit a new 52-week low on Wednesday after Bank of America downgraded the stock from a buy rating to a neutral rating. The company traded as low as $27.57 and last traded at $27.8350, with a volume of 3636722 shares changing hands. The stock had

Filtered for Smith & Nephew plcMore Headlines
04

Compare before deciding

Benchmark SNN against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Smith & Nephew plc (SNN)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
SNN logoSNNSmith & Nephew plcCurrent
$27.50$11.55B19.106.09%10.14%11.84%2.75%
ZBH logoZBHZimmer Biomet Holdings, Inc.
$93.98$18.18B26.477.2%9.48%6.36%—
SYK logoSYKStryker Corporation
$275.07$105.45B32.7511.16%14.43%16.36%—
BSX logoBSXBoston Scientific Corporation
$44.92$66.77B23.1519.87%17.47%14.76%—
HOLX logoHOLXHologic, Inc.
$76.01$16.97B30.531.74%13.18%11.01%—
CNMD logoCNMDCONMED Corporation
$46.17$1.38B30.585.16%4.12%5.51%—

Compare SNN vs Peers

Smith & Nephew plc (SNN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ZBH

Most directly comparable listed peer for SNN.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare SNN against a more recognizable public peer.

Peer Set

Compare Top 5

vs ZBH, SYK, BSX, HOLX

Get notified when SNN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

SNN Frequently Asked Questions

Smith & Nephew plc (SNN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Smith & Nephew plc's revenue?

Smith & Nephew plc (SNN) reported $12.24B in revenue for fiscal year 2025. This represents a 569% increase from $1.83B in 1996.

How fast is Smith & Nephew plc growing?

Smith & Nephew plc (SNN) grew revenue by 6.1% over the past year. This is steady growth.

Is SNN profitable?

Yes, Smith & Nephew plc (SNN) is profitable, generating $1.13B in net income for fiscal year 2025 (10.1% net margin).

Dividend & Returns
Does SNN pay dividends?

Yes, Smith & Nephew plc (SNN) pays a dividend with a yield of 2.75%. This makes it attractive for income-focused investors.

What is SNN's return on equity?

Smith & Nephew plc (SNN) has a return on equity (ROE) of 11.8%. This is reasonable for most industries.

What is Smith & Nephew plc's free cash flow?

Smith & Nephew plc (SNN) generated $1.65B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in SNN back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →